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Abstract. Lymphatic filariasis (LF) has been targeted for global elimination by 2020. The primary tool for the
program is mass drug administration (MDA) with antifilarial medications to reduce the source of microfilariae required
for mosquito transmission of the parasite. This strategy requires high MDA compliance rates. Egypt initiated a national
filariasis elimination program in 2000 that targeted approximately 2.7 million persons in 181 disease-endemic localities.
This study assessed factors associated with MDA compliance in year three of the Egyptian LF elimination program.
2,859 subjects were interviewed in six villages. The surveyed compliance rate for MDA in these villages was 85.3%
(95% confidence interval = 83.9–86.5%). Compliance with MDA was positively associated with LF knowledge scores,
male sex, and older age. Adverse events reported by 18.4% of participants were mild and more common in females.
This study has provided new information on factors associated with MDA compliance during Egypt’s successful LF
elimination program.
INTRODUCTION
Lymphatic filariasis (LF), also known as elephantiasis, is
endemic in 73 countries in the tropics and subtropics.1 An
estimated 40 million persons worldwide have significant
clinical manifestations of the disease, predominantly lymph-
edema, elephantiasis, and hydrocele. TheWorld Health Orga-
nization has targeted LF for global elimination by 2020.1
Microfilariae are filarial larvae that circulate in the blood of
infected persons, and these are ingested by mosquitoes when
they feed on infected humans. Ingested parasites develop in
mosquitoes over a period of two weeks to become larvae that
are infective for humans. The global elimination strategy was
designed to reduce the supply of microfilariae that can be
taken up by mosquitoes by mass administration of drugs that
clear microfilariae from the blood of endemic populations. If
high compliance rates can be achieved for mass drug adminis-
tration (MDA) over a period of years, this should reduce
infection rates to low levels and interrupt transmission. The
World Health Organization recommends MDA with a single
dose of diethylcarbamazine (DEC) combined with albendazole
annually for 4–6 years to eliminate LF in countries such as
Egypt, where there is no co-endemic onchocerciasis or loiasis.2
Egypt was one of the first countries to initiate a nationwide
program for LF elimination based on World Health Organi-
zation recommendations. In the year 2000, Ministry of Health
(MOH) officials made a strategic decision to provide MDA
with DEC and albendazole to the entire at risk population
from the start of the program. The alternative would have
been to scale up MDA over a period of years. The program
targeted approximately 2.7 million persons in 181 endemic
villages and towns in eight governorates.3 Pre-MDA infection
rates were as high as 19% in endemic communities.4 The
study reported here was conducted in 2002 after three rounds
of MDA had been distributed with high reported coverage
rates (85–90%). Social mobilization activities (distribution of
pamphlets and posters and short advertising programs on
television and the radio) delivered messages about the disease
to the target communities with the goal of enhancing commu-
nity awareness and participation in the MDA program.5
A study carried out in Haiti showed that knowledge about
filariasis and its mode of transmission was positively associ-
ated with MDA compliance.6 Another paper reported that
age, sex, and educational level influenced attitudes regarding
MDA for filariasis in India.7 Egypt’s LF elimination program
achieved unusually high MDA compliance rates. However,
little has been published on factors that affected compli-
ance with MDA during this program. Such information
might help other countries increase MDA compliance by
refining health education messages and improving drug dis-
tribution strategies.
Therefore, the primary objective of this study was to investi-
gate factors related to MDA compliance at the midpoint of
Egypt’s national LF elimination program (after three rounds of
MDA). The study also independently assessed reported MDA
compliance shortly after the country’s third round of MDA.
MATERIALS ANDMETHODS
Study participants. The study protocol was reviewed and
approved by an institutional review board at Ain Shams
University. Surveys were conducted approximately three
months after the third round of MDA in six semi-urban
villages with populations in the range of 10,000–20,000.
Three villages were in Giza governorate and three were in
the governorates of Menofiya, Kafr El Shiekh, and El
Sharkia in the Nile Delta. The Giza and Delta villages were
demographically similar, and their Wuchereria bancrofti
microfilaremia prevalence rates ranged from 3.5% to 11.5%
before initiation of the MDA program in 2000. Villages were
mapped and houses were numbered before the start of the
study. The surveys were performed in approximately 100
randomly selected houses per village. Interviewers recorded
demographic and MDA compliance information on pre-
printed forms after obtaining informed consent from study
subjects. Approximately 500 persons > 16 years of age were
assessed in each village.
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The compliance rate was calculated for all study partici-
pants based on their history of ingesting antifilarial medica-
tions during the third round of MDA. Thus, this study looked
at overall compliance among adults without correcting for
those who were not eligible for MDA (e.g., pregnant women).
Questionnaire. The questionnaire had 40 questions in 5
sections. The first section collected demographic informa-
tion. The second section evaluated the person’s knowledge
of the transmission, control, and prevention of LF. The third
section assessed knowledge of transmission, control, and pre-
vention of filariasis and elephantiasis, and this included a
question to determine whether the person understood the
relationship between LF and elephantiasis. Answers in this
section were used to generate a LF knowledge score, which
was expressed as a percentage based on a maximum of
50 points. The fourth section assessed the person’s participa-
tion in the previous MDA round. Questions in this section
assessed intake of the last dose of MDA, occurrence of
adverse events, treatment and severity of adverse events,
and whether the person had heard any publicity about
MDA before the last round. The fifth section included ques-
tions on whether the person had ever been given a diagnosis
of filariasis or had been treated for clinical filariasis (lymph-
edema or hydrocele).
The field work was conducted by 12 people, including 5
physicians, 3 senior medical students, and 4 experienced field
staff. Interviewers had special training sessions before the
survey to minimize interviewer bias. The training included
mock interviews using the questionnaire.
Data analysis. Double data entry and data cleaning were
performed by using SPSS data entry builder version 3.0 (SPSS,
Chicago, IL). All data analysis was conducted with the SPSS
Base Module Version 11.0.1. Knowledge about LF was
recoded into a knowledge score that had a total of 50 points.
The Mann-Whitney test was used to assess differences in
quantitative variables and a chi-square test was used to com-
pare proportions.
RESULTS
Interviews were conducted with 2,859 persons, including
1,527 in Giza villages and 1,332 in the Delta villages. The
study population included 1,555 female (54.4%) and 1,304
male participants (45.6%). The mean ± SD age of the studied
persons was 34.5 ± 16.0 years (median = 30 years and age
range = 16–92 years).
Knowledge about LF. Survey results on this topic are sum-
marized in Table 1. Most (90.5%) persons in the study had
heard about LF, but only 64.7% had heard of elephantiasis.
Forty-four percent of persons understood that the two terms
are related to a single disease. Persons reported a variety of
sources for their knowledge about LF. The most commonly
reported source of information was television advertisements
that were broadcast before each MDA round. Persons also
reported that they learned about LF from medical personnel
distributing MDA, relatives, and friends, and from written
materials, such as newspapers and posters.
The mean ± SD LF knowledge score for the studied sample
was 29.8 ± 20.7%. Twenty-three percent of persons scored
0%, 15% scored between 1% and 25%, 48% had a scores
between 26% and 50%, and 0.5% of persons had scores >
75%. The LF scores were higher in males (31.7 versus 28.3),
in persons < 30 years of age (33.4 versus 26.6), and in persons
with paying jobs (33.1 versus 26.8) (P < 0.01 for all of these
comparisons). The LF scores for persons living in Giza (29.1)
and the Nile Delta villages (30.6) were similar (P = 0.06).
Survey participants who could relate the two terms for fila-
riasis had significantly higher mean knowledge scores than
those who did not understand the relationship between the
two terms (36.3% versus 24.8%; P < 0.0001). Only 59.1% of
study participants knew that mosquitoes transmit filariasis.
Television advertisements seemed to have played an impor-
tant role in improving the study population’s knowledge about
the disease; persons who reported having watched television
announcements or stories about LF had significantly higher
mean LF knowledge scores than those who had not viewed
announcements or stories (P < 0.0001).
Reported compliance and adverse events after the third
round of MDA. Survey participants reported high compliance
with MDA (85.3%, 95% confidence interval = 83.9–86.5%)
(Table 2). Compliance rates were similar in theGiza andDelta
regions. The mean ± SD age for those who reported ingestion
of antifilarial medications in round 3 was 34.9 ± 16.2 years and
was significantly higher than those who had not complied with
MDA (31.9 ± 14.2 years). Persons who reported that they had
Table 1









Bed nets 339 11.9
Insecticides 627 21.9
No opinion 663 23.2
Treatment for filariasis
MDA 1,578 55.2
No opinion 998 34.9
*MDA = mass drug administration.
Table 2
Reported compliance for the third round of mass drug administration






Sex 0.026 1.11 (1.01–1.21)
M, n = 1,304 1,133 86.9
F, n = 1,555 1,305 83.9
Age, years 0.001 1.43 (1.16–1.76)
< 30, n = 1,337 1,108 82.9
³ 30, n = 1,522 1,330 87.4
Location of villages 0.53 1.0 (0.92–1.15)
Giza 1,308 85.7
Delta 1,130 84.8
Know mode of transmission 0.001 1.42 (1.16–1.75)
Yes, n = 1,720 1,498 87.1
No, n = 1,139 940 82.5
Television LF information 0.288 1.12 (0.9–1.3)
Yes, n = 1,791 1,537 85.8
No, n = 1,068 901 84.4
Relate LF and elephantiasis 0.008 1.33 (1.07–1.65)
Yes, n = 1,257 1,097 87.3
No, n = 1,602 1,341 83.7
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complied with MDA in round 3 had a higher mean LF knowl-
edge score than noncompliers, and compliance was also
higher in those who knew that elephantiasis and filariasis
referred to the same disease. However, MDA compliance
was not significantly associated with a history of viewing tele-
vision programs or advertisements related to LF or the elim-
ination program. Compliance rates differed by occupation,
but differences were small; students, farmers, and the unem-
ployed had slightly higher compliance rates than professionals
and shop owners (Table 3). Reasons provided by study par-
ticipants for noncompliance with MDA are shown in Table 4.
The most common reasons for noncompliance were absence
during MDA and pregnancy.
A logistic regression analysis was performed to determine
which variables had the highest impact on compliance with
MDA among the studied population. The variables that were
entered into the stepwise logistic regression model were sex,
age, overall LF knowledge score, and knowledge about the
mode of transmission of the disease. Results are shown in
Table 5. Age, awareness of the mode of transmission, and lack
of knowledge relating LF and elephantiasis were indepen-
dently related to compliance; younger persons and those who
were unaware of the mode of transmission were less compliant
withMDA. Sex was not independently linked to compliance.
Some study participants reported that they had experienced
adverse events (AEs) after the third round of MDA (n = 450
or 18.5% of 2,438 participants who reported taking MDA)
(Table 6). However, these AEs were mostly mild and transient;
dizziness and fatigue were most common. Adverse events after
MDA were more common in females than in males, but age
was not linked to AEs.
DISCUSSION
This study was conducted to assess knowledge about LF in
disease-endemic Egyptian villages during the National Filaria-
sis Elimination Program. It also gathered information on
reported compliance and AEs after the third round of MDA
in this campaign.
Most (90.1%) study participants had some knowledge
about filariasis. This percentage is similar to that reported by
Mathieu and others for an endemic area in Haiti.6 Mathieu
and others also reported that 36.4% of their study partici-
pants knew that mosquitoes transmit the disease. This value
was higher in the present study (59.1%). Males in our study
had better scores than females for knowledge about LF, and
they also had better compliance rates with MDA. This find-
ing is consistent with results from a study in India that found
that males were better informed about the disease and its
mode of transmission.7
Regarding compliance with MDA, our study participants
reported 85.3% compliance after the third round of MDA.
This value was slightly lower than the official coverage rates
reported by the Egyptian government after the third round
of MDA 93.3% (range 90–93% for all implementation units).
This finding may be explained in part by our inclusion of
persons who were not eligible for MDA in our compliance
calculation. Surveyed compliance excluding pregnant women
was 88.3%. However, the surveyed coverage rates and the
government rates are excellent and comparable to results
reported by Ramzy and others for four villages in Egypt
during the MDA program.3 These compliance rates are
higher than those reported frommany national LF elimination
Table 5





Relate LF and elephantiasis 3.4 0.06 1.23 (0.98–1.54)
Know mode of transmission 10.1 0.001 1.43 (1.14–1.79)
Age group† 16.0 0.000 1.54 (1.24–1.90)
*Calibration of the model: Hosmer and Lemeshow test c2 = 3.37, P = 0.642; model
discrimination: area under the curve = 0.578, 95% confidence interval = 0.549–0.607.
†The model considered age centiles (10-year intervals); the referent age group was the
lowest age group (< 20 years of age). This group was actually 16–20 years of age because we
only surveyed persons ³ 16 years of age.
Table 4
Reported reasons for non-compliance with mass drug administration,
Egypt
Causes of non-compliance No. %
Not at home 119 28.3
Pregnancy 98 23.3
Fear of adverse events 53 12.6
Team did not deliver drugs 46 10.9
Breast feeding 31 7.3
Dislike medicine 19 4.5
Liver disease 8 1.9
No excuse 47 11.2
Total 421 100.0
Table 3
Mass drug administration compliance by occupation, Egypt
Occupation No. % Compliance, No. (%)*
Housewife 1,254 43.9 1,041 (83.0)
Manual worker† 419 14.6 361 (86.2)
Student 393 13.7 349 (88.8)
Farmer 266 9.3 232 (87.2)
Merchant or office worker 191 6.7 164 (85.9)
Other‡ 99 3.5 79 (79.8)
No work 237 8.3 212 (89.5)
*Differences in compliance rates are significant by chi-square test (P = 0.05).
†Carpenter, plumber, builder, technical worker.
‡Professional or shop owner.
Table 6
Adverse events reported by survey participants approximately three
months after the third round of mass drug administration, Egypt






Nausea and vomiting 13 2.9
Fever 10 1.8
Other (scrotal or chest pain) 12 0.8
Duration
Few hours 328 72.9
1 day 89 19.8
> 1 day 33 7.3
No. %†
Sex
M 157 13.9 0.001 1.78 (1.4–2.2)
F 293 22.4
Age, years
< 30 206 18.6 0.8
³ 30 244 18.4
*Percentages of persons with any adverse event that reported different symptoms.
†Percentages of all persons interviewed who reported adverse events after taking MDA
(by sex and age). Note that noncompliant persons who did not receive mass drug administra-
tion were not included in this analysis.
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programs. For example, overall MDA coverage reported
from Haiti after the third round of MDA was 78.5%8 in
adults, and 61% in persons > 14 years of age. Moreover, in
India after six rounds of MDA, the coverage was only 54–
75% of the eligible population,9 and in Vanuatu the MDA
coverage after two years was 72%.10 Reported MDA cover-
age rates were around 45% in Ghana and Kenya.11 Males
reported higher MDA compliance than females in our study,
and this finding is consistent with results reported from Haiti,
where compliance was 77.7% in males and 54% in females.4
It was interesting to see that knowledge about the mode
of spread of LF was associated with better compliance with
MDA in the current study. This finding was statistically sig-
nificant by univariate and multivariate analysis, and the find-
ing is also consistent with results reported from Haiti.4,6 In
other parts of the world, educational messages related to LF
are often transmitted in person,12 but television seems to
have been important for delivering information about LF
and MDA in Egypt. This finding supports the decision of
the Egyptian MOH to invest heavily in electronic media for
publicizing the LF elimination program.5
It was also interesting that although younger persons and
shop owners had higher LF knowledge than the general sur-
veyed population, they also had lower MDA compliance
rates. This group may have been more likely to have been
absent at the time of drug distribution than other groups.
Special efforts may be needed to target subpopulations who
deny that they are at risk for LF. Fear of side effects or
complications of MDA has been a serious problem for pro-
grams in some parts of the world.13 However, only 12.6% of
the noncompliers in our study listed fear of AEs as a reason
for not taking MDA. Absence at the time of MDA and preg-
nancy were the main factors associated with noncompliance
in the present study.
This study has provided interesting information on disease/
project-specific knowledge in an LF-endemic population dur-
ing Egypt’s national LF elimination program. Systematic
post-MDA monitoring will be required to verify whether LF
has actually been elimination from the country.14 It is difficult
for a study like ours to capture the essence of what made
Egypt’s LF elimination program successful. However, we
believe that a number of factors contributed to this success.
First, Egypt has a strong primary health care network with
MOH units in most towns and larger villages. In addition, the
MOH had had significant experience with large-scale pro-
grams such as polio vaccination and schistosomiasis control
in LF-endemic areas.15 These factors are likely to have
increased the public’s confidence in the health system and
willingness to participate in the MDA program. Vigorous
social mobilization and health education activities were
developed for the LF elimination program, and these activi-
ties improved awareness of the importance of the disease
beforeMDA in disease-endemic areas.
The method used for MDA distribution in Egypt was
also important. Teams of health workers from local primary
health centers distributed the medications on a house-to-
house basis over a two-week period each year, and teams
directly observed ingestion of the pills in most cases. We
believe that this distribution method is preferable to distribu-
tion of MDA from fixed locations. The MOH and the pro-
gram also benefitted from partnerships with filariasis experts
from universities in Egypt and other countries. Finally, it
is important to recognize significant financial and technical
support that the MOH received from partner organizations,
such as the World Health Organization, GlaxoSmithKline,
and the Arab Fund for Social and Economic Development.
Public health experience and infrastructure, preparation,
planning, partnerships, and commitment (financial and politi-
cal) all helped to make this program successful. Although
recipes vary in details from country to country, most success-
ful LF elimination programs include these ingredients.
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